620 studies found for:
Cetuximab
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Completed |
Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer
|
||||
| 2 | Active, not recruiting |
Phase 1 and 2 Study of PX-866 and Cetuximab
|
||||
| 3 | Recruiting |
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
|
||||
| 4 | Active, not recruiting |
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
|
||||
| 5 | Completed |
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
|
||||
| 6 | Active, not recruiting |
A Trial Exploring the Efficacy of EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
|
||||
| 7 | Active, not recruiting |
Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours
|
||||
| 8 | Active, not recruiting |
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
|
||||
| 9 |
Completed
Has Results |
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
|
||||
| 10 | Recruiting |
Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients
|
||||
| 11 | Recruiting |
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
|
||||
| 12 | Completed |
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
|
||||
| 13 | Active, not recruiting |
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
|
||||
| 14 | Completed |
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
|
||||
| 15 | Recruiting |
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery
|
||||
| 16 | Terminated |
Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
|
||||
| 17 | Recruiting |
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
|
||||
| 18 | Withdrawn |
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
|
||||
| 19 |
Completed
Has Results |
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
|
||||
| 20 | Completed |
Cetuximab in Treating Patients With Advanced Solid Tumors
|
† Indicates status has not been verified in more than two years
